[Adenocarcinoma of the endometrium. The role of vaginal brachytherapy in the therapeutic sequence].
Surgery is the traditional treatment for endometrial carcinoma stage I and II. Radiotherapy is given to improve local control rate. Vaginal vault curietherapy can reduce vaginal recurrences rate. Chronology of curietherapy (pre or post operative) is under discussion. We have retrospectively analyzed treatment results of patients treated either with pre operative curietherapy (60 Gy) and then radical hysterectomy with bilateral salpingo oophorectomy (RH-BSO) (group 1), or with RH-BSO and then vaginal curietherapy (60 Gy) (group 2). Patients with bad prognostic factors (grade 3 and deep tumor invasion into the myometrium) received pelvic external irradiation and were excluded. 121 patients were in group 1, 63 patients were in group 2. All patients received curietherapy using Cesium 137 sources (one uterine and two vaginal sources in group 1, three vaginal sources in group 2). Total dose delivered to the reference volume was 60 Gy. Doses delivered to some reference points (vagina, rectum, bladder, pelvic wall) were calculated according to the ICRU recommendations. Surgery was at least RH-BSO performed either before or after curietherapy. 82 patients in group 1 and 44 in group 2 had a pelvic lymphadenectomy. Curietherapy data were comparable in the two groups according to the dose distribution to the vagina, rectum and bladder. Reference volume was smaller in the group 2. Local failure rate was 13% in group 1 and 10% in group 2. Distant metastases rate was 12% in group 1 and 9% in group 2. Five year actuarial survival rate was not statistically different between the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)
Calais
G
G
Clinique d'Oncologie et Radiothérapie, Hôpital Bretonneau, Tours.
Vitu
L
L
Descamps
P
P
Fignon
A
A
Reynaud-Bougnoux
A
A
Body
G
G
Lansac
J
J
Le Floch
O
O
D000230:Adenocarcinoma / Q000532:radiotherapy* / Q000601:surgery*; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods; D002588:Cesium Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007045:Hysterectomy, Vaginal; D008197:Lymph Node Excision; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011182:Postoperative Care; D011300:Preoperative Care; D011879:Radiotherapy Dosage; D012007:Rectum / Q000528:radiation effects; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D001743:Urinary Bladder / Q000528:radiation effects; D014594:Uterine Neoplasms / Q000532:radiotherapy* / Q000601:surgery*; D014621:Vagina / Q000528:radiation effects
D002588:Cesium Radioisotopes